OOF is under clinical development by DongKoo Bio & Pharma and currently in Phase I for Idiopathic (Essential) Hypertension. According to GlobalData, Phase I drugs for Idiopathic (Essential) Hypertension does not have sufficient historical data to build an indication benchmark PTSR for Phase I. GlobalData uses proprietary data and analytics to create drugs-specific PTSR and LoA in the OOF LoA Report. Buy the report here.
GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.
OOF overview
OOF is under development for the treatment of hypertension and essential hypertension. It is administered orally.
DongKoo Bio & Pharma overview
DongKoo Bio & Pharma (DongKoo) develops, manufactures, and exports generic drugs and provides contract manufacturing services. The company’s product portfolio includes prescribed medicines, including digestants; antiplatelet agents, allergics; nonsteroidal anti-inflammatory drugs decongestants and nasal preparation products; and oral hypoglycemic agents, non-medical products, CMO products, medical apparatus such as smart X, a stem-cell extraction kit, and cosmetics. It offers products in various forms, such as soft gelatin capsules, hard capsules, tablets, powders or granules, externals and liquids. The company has a presence across Vietnam, New Zealand, Thailand, Hong Kong, and Singapore. DongKoo is headquartered in Seoul, South Korea.
For a complete picture of OOF’s drug-specific PTSR and LoA scores, buy the report here.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.
